검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Anti-B Cell Maturation Antigen (BCMA, Anti-B Cell Maturation Antigen, Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells) National Cancer Institute (NCI)·BCMA ORR 97.1% |
|---|---|
Overview Program | Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells |
Overview Company | National Cancer Institute (NCI) |
Overview Modality | CGT |
Overview Target | BCMA |
Overview Indication | Myeloma-Multiple; Myeloma, Plasma-Cell |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Mechanism | targets for bsAbs on multiple myeloma cells are B cell maturation antigen (BCMA), G-protein-coupled receptor family C group 5 member D (GPRC5D), and Fc receptor |
MoA Biomarker | BCMA) is a high |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pd |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | interstitial lung disease |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 97.1% |
Clinical ORR | 97.1% |
Clinical PFS | NA |
Clinical OS | NA |
Clinical Result source | ClinicalTrials.gov NCT03548207 |
Clinical Data Tier / Score | A · 67 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Anti-B Cell Maturation Antigen (BCMA, Anti-B Cell Maturation Antigen, Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells) National Cancer Institute (NCI)·BCMA ORR 97.1% |
|---|---|
Overview Program | Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells |
Overview Company | National Cancer Institute (NCI) |
Overview Modality | CGT |
Overview Target | BCMA |
Overview Indication | Myeloma-Multiple; Myeloma, Plasma-Cell |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Mechanism | targets for bsAbs on multiple myeloma cells are B cell maturation antigen (BCMA), G-protein-coupled receptor family C group 5 member D (GPRC5D), and Fc receptor |
MoA Biomarker | BCMA) is a high |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pd |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | interstitial lung disease |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 97.1% |
Clinical ORR | 97.1% |
Clinical PFS | NA |
Clinical OS | NA |
Clinical Result source | ClinicalTrials.gov NCT03548207 |
Clinical Data Tier / Score | A · 67 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교